Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers
| Autor: | Wim Vos, Claire J.P. Boog, Robert Ploemacher, D. W J G van Breugel, M. van Pel |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Oncology medicine.medical_specialty Transplantation Conditioning CD3 Complex Haploidy In Vitro Techniques Treosulfan Immune tolerance Major Histocompatibility Complex Mice Internal medicine Immune Tolerance medicine Animals Antineoplastic Agents Alkylating Busulfan Bone Marrow Transplantation Transplantation Chimera Transplantation business.industry Antibodies Monoclonal Skin Transplantation Hematology Myeloablative Agonists Mice Inbred C57BL Tolerance induction Regimen Toxicity Immunology business medicine.drug |
| Zdroj: | Bone Marrow Transplantation. 33:153-159 |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/sj.bmt.1704333 |
| Popis: | Treosulfan is a water-soluble structural analog of busulfan, acting as a prodrug of alkylating epoxide species. It does not induce severe hepatotoxicity or veno-occlusive disease at or above the maximum tolerated dose, lacks significant nonhematological toxicity and has a limited organ toxicity. It is mainly indicated for the treatment of patients with ovarian cancer. In the present study, we report that permanent donor-specific tolerance and stable mixed multilineage chimerism can successfully be achieved across haploidentical MHC barriers when Treosulfan is administered in combination with anti-T-cell mAb and T-cell-depleted donor bone marrow cells. Furthermore, we show that less T-cell suppression is required when Treosulfan is included in the conditioning regimen. In conclusion, Treosulfan is a well-tolerated myeloablative agent with a low toxicity, and is a promising candidate drug for conditioning prior to bone marrow transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|